These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9302140)

  • 1. Serial tissue polypeptide specific antigen determination in the followup of hormone treated carcinoma of the prostate.
    Kramer G; Steiner GE; Madersbacher S; Stulnig T; Lang T; Marberger M
    J Urol; 1997 Oct; 158(4):1446-51. PubMed ID: 9302140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
    Tarle M
    Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer.
    Kwak C; Jeong SJ; Park MS; Lee E; Lee SE
    J Urol; 2002 Sep; 168(3):995-1000. PubMed ID: 12187207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum markers for monitoring of prostatic carcinoma.
    Polito M; Minardi D; Recchioni A; Giannulis I; De Sio G; Muzzonigro G
    Prostate; 1997 Nov; 33(3):208-16. PubMed ID: 9365550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
    Stege R; Grande M; Carlström K; Tribukait B; Pousette A
    Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurements of free and total PSA, tissue polypeptide-specific antigen (TPS), and CYFRA 21-1 in prostate cancer patients under intermittent androgen suppression therapy.
    Theyer G; Dürer A; Theyer U; Haberl I; Ulsperger E; Baumgartner G; Hamilton G
    Prostate; 1999 Oct; 41(2):71-7. PubMed ID: 10477903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine variations in patients with hormone treated prostate cancer.
    Wise GJ; Marella VK; Talluri G; Shirazian D
    J Urol; 2000 Sep; 164(3 Pt 1):722-5. PubMed ID: 10953133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A more objective staging of advanced prostate cancer--routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values.
    Tarle M; Frković-Grazio S; Kraljić I; Kovacić K
    Prostate; 1994; 24(3):143-8. PubMed ID: 7509485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
    Tarle M; Kovacić K; Kastelan M
    Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
    Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
    Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum TPS, PSA, and PAP values in relapsing stage D2 adenocarcinoma of the prostate.
    Kraljić I; Kovacić K; Tarle M
    Urol Res; 1994; 22(5):329-32. PubMed ID: 7533445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined androgen blockade in the management of advanced prostate cancer: a sensible or ostensible approach.
    Ansari MS; Gupta NP; Hemal AK; Dogra PN; Seth A
    Int J Urol; 2004 Dec; 11(12):1092-6. PubMed ID: 15663681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.
    Miller JI; Ahmann FR; Drach GW; Emerson SS; Bottaccini MR
    J Urol; 1992 Mar; 147(3 Pt 2):956-61. PubMed ID: 1371568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma.
    Kil PJ; Goldschmidt HM; Wieggers BJ; Kariakine OB; Studer UE; Whelan P; Hetherington J; de Reijke TM; Hoekstra JW; Collette L
    Eur Urol; 2003 Jan; 43(1):31-8. PubMed ID: 12507541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
    Stewart AJ; Scher HI; Chen MH; McLeod DG; Carroll PR; Moul JW; D'Amico AV
    J Clin Oncol; 2005 Sep; 23(27):6556-60. PubMed ID: 16170163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.
    Beer TM; Garzotto M; Eilers KM; Lemmon D; Wersinger EM
    Urology; 2004 Feb; 63(2):342-7. PubMed ID: 14972486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.
    Sridhara R; Eisenberger MA; Sinibaldi VJ; Reyno LM; Egorin MJ
    J Clin Oncol; 1995 Dec; 13(12):2944-53. PubMed ID: 8523059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of tissue polypeptide specific antigen in the detection of prostate cancer.
    Onur R; Orhan I; Ilhan N; Semercioz A
    Urol Int; 2002; 69(4):278-82. PubMed ID: 12444283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
    Oosterlinck W; Mattelaer J; Casselman J; Van Velthoven R; Derde MP; Kaufman L
    Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.